Online inquiry

IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3099MR)

This product GTTS-WQ3099MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FASLG gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 356
UniProt ID Q53ZZ1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3099MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2708MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG103
GTTS-WQ9142MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ8706MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ1389MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ2903MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ15887MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ13482MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ13008MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW